CGT-001 / Carbon Biosci - LARVOL DELTA

Carbon Biosciences Announces Four Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting (PRNewswire) - "Carbon Biosciences...announced that it has been selected for an oral presentation at the Presidential Symposium during the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place from May 7-11, 2024, in Baltimore, MD. The presentation will highlight the development of CGT-001, a potential gene therapy for the treatment of Cystic Fibrosis (CF), which utilizes the novel pulmonary targeting vector, CBN-1000, capable of delivering genes beyond the capacity of AAV. In addition, the Company will be featuring three poster presentations detailing new preclinical data, and manufacturing process development and analytical characterization for two of its novel viral gene therapy vectors."

Preclinical • Cystic Fibrosis

Manufacturing Process Development and Analytical Characterization of CBN-1000, a New Viral Vector Derived from Human Bocavirus (ASGCT 2024) - "An affinity chromatography-free purification process has also been developed which results in high purity vector product. The process development, scale-up and manufacturing of this new hybrid vector and in-depth characterization of CGT-001 will be described."

Viral vector • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases • CFTR

Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline (Businesswire) - "Carbon’s lead candidate, CGT-001, targets lung tissue with demonstrated upper airway tissue tropism and repeatable dosing in gold-standard cystic fibrosis models. Financing will advance its lead cystic fibrosis program towards the clinic and the development of its proprietary platform....Carbon Biosciences ('Carbon'), a Longwood Fund founded biotech company and emerging leader in the development of novel parvovirus-derived gene therapies, today announced a $38 million Series A financing led by Agent Capital."

Financing • Cystic Fibrosis

Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis (Businesswire) - "The Cystic Fibrosis Foundation today announced its investment of $6 million in Carbon Biosciences to support the company‘s preclinical research into an innovative gene therapy approach for cystic fibrosis....Carbon Biosciences aims to deliver a functional cystic fibrosis transmembrane conductance regulator (CFTR) gene directly into the lung cells of people with cystic fibrosis using a cutting-edge approach that has the potential to provide a treatment for all people living with CF, regardless of mutation."

Financing • Cystic Fibrosis